Laboratory of Physiopharmacology, University of Antwerp, 2610 Antwerp, Belgium.
Laboratory of Neurochemistry and Behaviour, University of Antwerp, 2610 Antwerp, Belgium.
Int J Mol Sci. 2022 Mar 1;23(5):2738. doi: 10.3390/ijms23052738.
Given the unprecedented rise in the world's population, the prevalence of prominent age-related disorders, like cardiovascular disease and dementia, will further increase. Recent experimental and epidemiological evidence suggests a mechanistic overlap between cardiovascular disease and dementia with a specific focus on the linkage between arterial stiffness, a strong independent predictor of cardiovascular disease, and/or hypertension with Alzheimer's disease. In the present study, we investigated whether pharmacological induction of arterial stiffness and hypertension with angiotensin II (1 µg·kg·min for 28 days via an osmotic minipump) impairs the progression of Alzheimer's disease in two mouse models (hAPP23 and hAPPswe/PSEN1dE9 mice). Our results show increased arterial stiffness in vivo and hypertension in addition to cardiac hypertrophy after angiotensin II treatment. However, visuospatial learning and memory and pathological cerebral amyloid load in both Alzheimer's disease mouse models were not further impaired. It is likely that the 28-day treatment period with angiotensin II was too short to observe additional effects on cognition and cerebral pathology.
鉴于世界人口的空前增长,心血管疾病和痴呆等突出的与年龄相关的疾病的患病率将进一步上升。最近的实验和流行病学证据表明,心血管疾病和痴呆之间存在机制上的重叠,特别是动脉僵硬、心血管疾病的强有力独立预测因子,以及/或高血压与阿尔茨海默病之间的联系。在本研究中,我们研究了血管紧张素 II(通过渗透微型泵以 1µg·kg·min 的剂量持续 28 天)诱导的动脉僵硬和高血压是否会损害两种小鼠模型(hAPP23 和 hAPPswe/PSEN1dE9 小鼠)中阿尔茨海默病的进展。我们的结果显示,血管紧张素 II 处理后体内动脉僵硬增加,同时伴有高血压和心脏肥大。然而,两种阿尔茨海默病小鼠模型的视觉空间学习和记忆以及病理性脑淀粉样蛋白负荷并没有进一步受损。可能是因为血管紧张素 II 的 28 天治疗期太短,无法观察到对认知和大脑病理的额外影响。